NASHUA, N.H. — August 1, 2017 – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that management will be providing a corporate update at the Canaccord Genuity 37th Annual Growth Conference, being held August 9-10 in Boston, Massachusetts.
Date: Thursday, August 10
Time: 2:00pm Eastern Time
Location: InterContinental Hotel, Hong Kong Room
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
For iCAD investor relations:
Bob Yedid, (646)-597-6989
For iCAD media inquiries:
Berry & Company Public Relations, LLC
Lynn Granito, 212-253-8881